Drug Trial Radar · NCT05604885
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Last checked: Nov 19, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Nov 30, 2022
Primary completion
Aug 28, 2023
Study completion Aug 28, 2023
Sponsor
- Lead sponsor
- SynAct Pharma ApsIndustry
- Sponsor type
- Industry
- Collaborators
- NBCD A/S
- First posted
- Nov 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult RA patients with an inadequate response to MTX alone.
Conditions
- Rheumatoid Arthritis
Interventions
AP1189, 60 mgDrug
AP1189 tablets for oral use
AP1189, 80 mgDrug
AP1189 tablets for oral use
AP1189, 100 mgDrug
AP1189 tablets for oral use
PlaceboDrug
Matching placebo tablets for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change in ACR20Time frame: 4 weeks
- Part B: Change in ACR20Time frame: 12 weeks
- Number of reported Adverse EventsTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Timofei Mosneaga Republican Clinical Hospital
Chisinau, Moldova
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.